Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention

Pannipa Suwannasom1, Korakoth Towashiraporn2, Worawut Roongsangmanoon3

  • 1Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

PubMed

Insights

Drug-coated balloons (DCBs) offer an alternative to drug-eluting stents (DESs) in percutaneous coronary intervention (PCI). This consensus provides guidance on DCB use, lesion preparation, and antiplatelet therapy for optimal patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology

Background:

  • Drug-coated balloons (DCBs) deliver antiproliferative drugs without permanent scaffolds in percutaneous coronary intervention (PCI).
  • Indications for DCBs have expanded from in-stent restenosis (ISR) to small vessel and bifurcation lesions.
  • Variability exists in patient/lesion selection, preparation, and dual antiplatelet therapy (DAPT) duration post-DCB angioplasty.

Purpose of the Study:

  • To establish a consensus statement on the use of DCBs in coronary interventions.
  • To provide structured recommendations for optimal DCB therapy in clinical practice.

Main Methods:

  • Systematic review of randomized controlled trials, meta-analyses, and real-world studies by the CIAT expert panel.
  • Appraisal of procedural strategies, imaging guidance, physiologic assessment, and antiplatelet protocols.
  • Recommendations developed and voted on, with consensus defined by 80% agreement.

Main Results:

  • DCBs show comparable outcomes to drug-eluting stents (DESs) in selected lesions, allowing shorter DAPT durations.
  • Optimal DCB outcomes depend on meticulous lesion preparation, appropriate balloon sizing, and controlled dissection.
  • Intravascular imaging, physiologic assessment, and hybrid strategies enhance procedural precision for complex cases.

Conclusions:

  • DCB angioplasty serves as a viable alternative or complement to DESs in various clinical and anatomical settings.
  • The CIAT consensus offers structured guidance for implementing DCB therapy.
  • Adherence to recommendations can optimize patient outcomes and support contemporary DCB practice.

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...